[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.173.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 161
Citations 0
Observation
October 12, 2016

Rituximab for the Treatment of Isolated Refractory Desquamative Gingivitis Due to Mucous Membrane Pemphigoid

Author Affiliations
  • 1Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
  • 2University Institute of Clinical Chemistry and Center of Laboratory Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
  • 3Department of Oral Surgery and Stomatology, School of Dental Medicine, University of Bern, Bern, Switzerland
JAMA Dermatol. Published online October 12, 2016. doi:10.1001/jamadermatol.2016.3434

Mucous membrane pemphigoid (MMP) is a rare autoimmune subepithelial blistering disorder characterized by predominant involvement of the mucosae, a chronic course, and a tendency toward scarring of the affected areas.1 A relatively common sign of MMP is desquamative gingivitis. We describe our experience using rituximab to treat 3 patients with recalcitrant desquamative gingivitis as the sole manifestation of MMP. Diagnosis of MMP was based on clinical and immunopathological criteria.1,2 The MMP mucosal activity score (MAS), which was used for the evaluation of the response, was retrospectively calculated based on the clinical pictures and notes.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×